Multiple Sclerosis Clinical Trial 20203202

[LCID Study Number: 20203202]

An Observational Study Of Ocrelizumab - Treated Patients With Multiple Sclerosis To Determine The Incidence And Mortality Rates Of Breast Cancer And All Malignancies (Verismo Study)

The purpose of this study is to determine the incidence rate of breast cancer and all malignancies following the first ocrelizumab treatment among patients with multiple sclerosis (MS).

Disease/Condition: Multiple Sclerosis

Department: Neurology

Location(s): Lahey Hospital & Medical Center (Burlington)

Primary Contact Email: [email protected]

Protocol #: 20203202
Principal Investigator(s): Matthew T. McAdams
Study Coordinator(s): Catia Melo
Trial Phase: Sponsor Initiated Study Observational